Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab

Fig. 3

Percentange of circulating Th17 (IL-17A) and Th22 (IL-22) in stimulated PBMCs of CAMPs patients before and after ustekinumab treatment. a On the left, representative flow cytometry dot plots of the intracellular expression of IL-17 and IL-22 from CAMPS patients (Pt) (at baseline, at week 4 and at week 24); (b) On the right: the change in circulating frequency of Th17 and Th22 cells in CAMPS patients and pediatric healthy controls (CTRLs) before and after ustekinumab treatment (at baseline, at week 4, at week 16). Each point represents a sample

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096